


The Efficacy of Avacincaptad Pegol in Geographic Atrophy: GATHER1 and GATHER2 Results


Avacincaptad pegol is a pegylated RNA aptamer designed to be a specific inhibitor of complement C5. The complement system plays a key role in the specialized immune defense mechanisms of the retina and the inhibition of C5 slows the inflammation and cell death associated with the development and progression of geographic atrophy (GA). GATHER1 is a Phase 2/3 study looking at the mean change in GA area from baseline over 12 months. GATHER2 is a Phase 3 study looking at the mean rate of growth (slope) in geographic atrophy area from baseline over 12 months.

Khanani AM, et al. Presented at The Retina Society 55th Annual Scientific Meeting; November 2-5, 2022; Pasadena, CA.


C5 inhibition potentially preserves anti-inflammatory properties of C3a.



GATHER1 was a phase 2/3, international, prospective, randomized, double-masked, sham-controlled trial to analyze mean change in GA area from baseline to Month 12



GATHER2 was a phase 3, international, multicenter, prospective, randomized, double-masked, sham-controlled study to analyze mean rate of growth (slope) in GA area from baseline to Month 12 (square root transformation)



Inclusion criteria for GATHER1 & GATHER2

- Age ≥50 years
- BCVA between 20/25 and 20/320
- GA lesion:
 - Non-center point involving
 - GA in part within 1500 μm from the foveal center
 - Total area between 2.5 mm² and 17.5 mm² (1-7 DA, respectively)
 - If multifocal lesions, at least 1 lesion had to be ≥1.25 mm² (0.5 DA)


Exclusion criteria for GATHER1 & GATHER2

- Evidence of CNV in either eye at baseline
- GA secondary to any condition other than AMD in either eye
- Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye (except oral vitamin or mineral supplements)
- Any ocular condition in study eye that could progress during the study and potentially affect central vision or otherwise act as a confounding factor
- Any sign of diabetic retinopathy in either eye


AMD = age-related macular degeneration; BCVA = best-corrected visual acuity; CNV = choroidal neovascularization; DA = disc area; GA = geographic atrophy.

A significant reduction in the mean change in GA area and mean rate of GA growth (slope analysis) from baseline to Month 12 was observed in both GATHER1 & GATHER2, respectively.

GATHER1




GATHER2




ACP = avacincaptad pegol; CI = confidence interval; GA = geographic atrophy.

The reduction in mean rate of observed GA growth (slope analysis) demonstrated consistent efficacy results between the two studies.

GATHER1



GATHER2



Note: The primary analysis for GATHER1 (mean change in square root transformed GA area from baseline to month 12 [mm]) is consistent with the slope analysis utilizing observed data. The estimates for the GATHER1 ACP 2 mg group vs sham are from the MMRM model, should not be interpreted as directly observed data, including data from groups with different randomization ratios in Part 1 and Part 2 of the trial, and should not be interpreted as directly observed data.

^aNon-square root transformation; ^bDescriptive P-value.

ACP = avacincaptad pegol; CI = confidence interval; GA = geographic atrophy.

Conclusion

Avacincaptad pegol is the **first investigational therapy in GA** to achieve the 12-month prespecified, primary endpoint, in two pivotal, phase 3 studies.